BDBM347674 3-Ethynyl-5-((4-((4-(3-(3-(2-methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido) naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-N-(2-morpholinoethyl)benzamide::US9790209, Example 15
SMILES: Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(Oc2ccnc(Nc3cc(cc(c3)C(=O)NCCN3CCOCC3)C#C)n2)c2ccccc12)C(C)(C)C#C
InChI Key: InChIKey=HZKOUKPIDXDOOI-UHFFFAOYSA-N
Data: 4 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5-hydroxytryptamine receptor 2A (Homo sapiens (Human)) | BDBM347674 (3-Ethynyl-5-((4-((4-(3-(3-(2-methylbut-3-yn-2-yl)-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 67 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Glycogen synthase kinase-3 (Homo sapiens (Human)) | BDBM347674 (3-Ethynyl-5-((4-((4-(3-(3-(2-methylbut-3-yn-2-yl)-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 296 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase SYK (Homo sapiens (Human)) | BDBM347674 (3-Ethynyl-5-((4-((4-(3-(3-(2-methylbut-3-yn-2-yl)-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 40 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Proto-oncogene tyrosine-protein kinase Src (Homo sapiens (Human)) | BDBM347674 (3-Ethynyl-5-((4-((4-(3-(3-(2-methylbut-3-yn-2-yl)-...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 16 | n/a | n/a | n/a | n/a | n/a | n/a |
Respivert Limited; Topivert Pharma Limited US Patent | Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri... | US Patent US9790209 (2017) BindingDB Entry DOI: 10.7270/Q2TQ63PS | |||||||||||
More data for this Ligand-Target Pair |